The disclosure of proven cardiorenal benefits with certain antidiabetic agents was supposed
to herald a new era in the management of type 2 diabetes (T2D), especially for the many …

Aim To assess the effects of sodium‐glucoseco‐transporter‐2 (SGLT2) inhibitors on diabetic
ketoacidosis (DKA) in patients with type 2 diabetes. Materials and Methods We searched …

Guidelines RSSDI-ESI Clinical Practice Recommendations for the Management of Type 2
Diabetes Mellitus 2020Table. No title available.

Introduction: Sodium-glucose cotransporter type 2 inhibitors (SGLT2is) are recommended
after metformin for a large spectrum of patients with type 2 diabetes, because of a favorable …

Approximately half of all patients with type 2 diabetes (T2D) develop a certain degree of
renal impairment. In many of them, chronic kidney disease (CKD) progresses over time …

Aims The objective of the study was to quantify the association between SGLT2 inhibitors
and genital mycotic infection and between SGLT2 inhibitors and urinary tract infection (UTI) …

Background Perioperative diabetic ketoacidosis (DKA) with near-normal blood glucose
concentrations, termed euglycaemic ketoacidosis (EDKA), is an adverse effect associated …

Given that the increase in the aging population has grown into one of the largest public
health issues, inflammation and oxidative stress, which are closely associated with the aging …

Euglycemic diabetic ketoacidosis (DKA) is an acute life-threatening metabolic emergency
characterized by ketoacidosis and relatively lower blood glucose (less than 11 mmol/L). The …

Abstract Sodium-glucose cotransporter-2 (SGLT2) inhibitors are drugs designed to lower
plasma glucose concentration by inhibiting Na+-glucose–coupled transport in the proximal …